Navigation Links
BIDMC scientists awarded grants from Michael J. Fox Foundation for Parkinson's research
Date:11/18/2009

BOSTON -- Beth Israel Deaconess Medical Center (BIDMC) neurologists Alvaro Pascual-Leone, MD, PhD, and Daniel Tarsy, MD, have been awarded grants totaling more than $1.5 million from the Michael J. Fox Foundation for Parkinson's Research (MJFF) to conduct investigations aimed at improving the quality of life for patients with Parkinson's disease.

A chronic, degenerative disorder of the nervous system that affects one in 100 individuals over age 60, Parkinson's disease results from diminished levels of dopamine, the brain's chemical messenger responsible for transmitting the signals that enable us to coordinate movements. Although Parkinson's disease typically results in tremor, rigidity and other motor symptoms, a number of non-motor symptoms, including depression, cognitive impairment, and sleep problems can also affect patients with Parkinson's disease and, in many cases, can be even more disabling than the motor symptoms.

Pascual-Leone, Director of BIDMC's Berenson-Allen Center for Noninvasive Brain Stimulation, will oversee a three-year $1.498 million grant to investigate the use of repetitive transcranial magnetic stimulation (rTMS) therapy to control symptoms of Parkinson's disease. As part of the study, 160 patients will be enrolled in clinical trials at BIDMC and at three other North American centers including the University of Florida in Gainesville, the University of California in Los Angeles, and the Toronto (Canada) Western Research Institute-University of Toronto.

"Depression is very common among patients with Parkinson's disease and evidence suggests that it is not merely a response to chronic illness or motor impairments but, in fact, results from factors related to the degenerative brain process itself," notes Pascual-Leone, whose pioneering work has demonstrated that TMS therapy in which a mild electric current is delivered through a magnetic coil placed over a patient's scalp to help adjust brain signals that have gone awry can successfully treat depression in patients who have not responded to other therapies.

"Often patients with Parkinson's disease have significant motor problems despite treatment with medications," explains Pascual-Leone. "In our study, noninvasive brain stimulation will target one or both of two brain regions involved in motor or mood symptoms. We predict that rTMS will improve motor symptoms, depression, or both, depending on which brain regions are stimulated, and consequently, will become a valuable adjunct to medications."

In the second MJFF-funded project, Daniel Tarsy, MD, Director of BIDMC's Parkinson's Disease Center, will lead a study comparing two types of speech and voice therapy to determine which is more effective in treating the decreased voice volume experienced by many Parkinson's patients.

"Impaired speech can cause patients to suffer distress, social embarrassment and social isolation," explains Tarsy. "Musical therapy is currently being used for rehabilitation from other types of neurological conditions, such as language impairment following stroke. If singing therapy can also improve voice and speech disorders resulting from Parkinson's disease, this would represent an important alternative to existing speech therapy techniques."


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related medicine news :

1. BIDMC Chairman of Neurology Clifford B. Saper, M.D., Ph.D., elected to Institute of Medicine
2. Low-Carb Diet Referenced in BIDMC Study Not Related to Atkins
3. BIDMC scientists receive creativity awards from Prostate Cancer Foundation
4. Biotech company cofounded by BIDMC scientists targets natural killer T-cells
5. Healthcare Data Services (HDS) Announces Contract with Beth Israel Deaconess Physician Organization (BIDPO) and Beth Israel Deaconess Medical Center (BIDMC)
6. BIDMC Dyslexia Research Lab celebrates 25th anniversary
7. Scientists find molecular trigger that helps prevent aging and disease
8. Chinese Scientists Develop Database on the Liver
9. Scientists Grow New Penile Tissue in the Lab
10. Social Network for Translational Scientists Launched
11. Antipsychotic Medications Cause Substantial Weight Gain in Children and Adolescents, According to Scientists at the Feinstein Institute for Medical Research and Zucker Hillside Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... New York (PRWEB) , ... February 05, 2016 , ... ... use and find themselves having to wait longer to access the treadmills. It’s a ... New Year’s resolutions to lose weight and get in shape by joining gyms, starting ...
(Date:2/5/2016)... ... 2016 , ... Pivot Point Consulting, a leading national Healthcare ... Services for HIT Implementation Support & Staffing report with an outstanding score of ... healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. , ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Stuart Bentkover, ... technology, the PicoSure. Designed to provide the most effective tattoo removal today, Dr. Bentkover ... unmatched results. , Developed by Cynosure, the PicoSure has been approved by the Food ...
(Date:2/5/2016)... Pekin, IL (PRWEB) , ... February 05, 2016 , ... ... in disguised form as a dream. A hallmark feature of patients with eating disorders ... and needs. The eating disorder behaviors and obsessions are regarded as maladaptive means for ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June 9-10, ... a continuing medical education (CME) event presented by the Association for Comprehensive Care ... first for ACCORD, whose mission is to provide education, tools, and resources to ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Syneron Medical Ltd. (NASDAQ: ELOS ... today that William Griffing , Chief Executive ... to participate in the Leerink Partners 5 th ... 2016 in New York City ... meet with the Mr. Griffing and will include ...
(Date:2/5/2016)... 2016 http://www.researchandmarkets.com/research/jsc97m/global ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, ... their offering. --> http://www.researchandmarkets.com/research/jsc97m/global ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, ... their offering. --> Research ...
(Date:2/5/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... underwritten secondary offering of 11,027,558 shares of its common ... of Blackstone and Goldman Sachs.  The shares are being ... $96.45 per share. The selling stockholders will receive all ... nor any of its directors, officers or other stockholders ...
Breaking Medicine Technology: